Propanc Biopharma plans Phase 1b trial for cancer drug PRP Aug 12, 2026 08:32AM
Propanc reports 90%+ tumor growth inhibition for PRP in pancreatic cancer Aug 6, 2026 08:31AM
Propanc Biopharma reports preclinical data showing 90% tumor inhibition Aug 6, 2026 08:31AM
Propanc publishes recombinant proenzyme study in peer-reviewed journal Jul 21, 2026 08:31AM
Propanc Biopharma signs MOU with Avance Clinical for Phase 1 trial Jul 7, 2026 08:33AM


May 15, 2026 08:45AM Propanc Biopharma reports Q3 results, signs research deals
Mar 12, 2026 08:45AM Propanc Biopharma reports tumor inhibition data for pancreatic cancer therapy
Mar 3, 2026 08:46AM Propanc Biopharma reports tumor growth inhibition in preclinical study
Feb 18, 2026 08:45AM Propanc Biopharma files four patent applications, secures $100M facility
Feb 5, 2026 08:45AM Propanc Biopharma plans phase 1b trial for cancer therapy PRP in 2026
Jan 27, 2026 08:45AM Propanc Biopharma files fourth provisional patent in two months
Jan 20, 2026 08:45AM Propanc Biopharma files patent for synthetic cancer therapy production
Jan 15, 2026 08:45AM Propanc Biopharma plans Phase I/II trials for pancreatic cancer drug
Jan 13, 2026 08:45AM Propanc Biopharma plans Phase 1B cancer trial in 2026
Dec 30, 2025 06:05AM Propanc Biopharma, Inc. (PPCB) files for 2M share offering by selling stockholders
Dec 1, 2025 08:45AM Propanc Biopharma requests Spain license for cancer, fibrosis patents
Nov 4, 2025 07:00AM Propanc Biopharma plans to acquire digital asset treasury companies
Sep 17, 2025 08:45AM Propanc Biopharma receives fourth US patent for proenzyme composition
Aug 25, 2025 07:30AM Propanc Biopharma raises $4 million in Nasdaq debut, plans cancer trials
May 30, 2025 03:42PM Propanc Biopharma, Inc. (PPCB) Files for 1M Share IPO at $4-$6/sh, Nasdaq Uplisting